April 17, 2023
VIA EDGAR
David Edgar
Division of Corporation Finance
Office of Technology
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: Enfusion, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 10, 2023
Form 8-K Furnished on March 7, 2023
File No. 001-40949
Dear Mr. Edgar:
Enfusion, Inc. (“we,” “us” and “our”) hereby acknowledges receipt of the letter (the “Comment Letter”), dated April 14, 2023, containing comments of the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission.
The Comment Letter requests that we respond to the Staff’s comments within ten business days or advise the Staff when we will provide the Staff with our responses. As previously discussed, we respectfully request an extension of time to respond to the Comment Letter so that we can devote appropriate time and resources to consider the Staff’s comments and to complete our responses. We expect to provide our responses to the Comment Letter no later than May 12, 2023.
If you have any questions, please do not hesitate to call the undersigned at (312) 724-8981.
| Sincerely, | |
| /s/ Matthew R. Campobasso | |
| Matthew R. Campobasso | |
| General Counsel and Secretary |
| cc: | Brad Herring, Chief Financial Officer, Enfusion, Inc. |